S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
NASDAQ:ACET

Adicet Bio - ACET Stock Forecast, Price & News

$17.04
-1.11 (-6.12%)
(As of 08/9/2022 10:10 AM ET)
Add
Compare
Today's Range
$17.00
$17.99
50-Day Range
$10.83
$18.74
52-Week Range
$6.25
$21.17
Volume
2,408 shs
Average Volume
327,352 shs
Market Capitalization
$681.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.29

Adicet Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
61.4% Upside
$29.29 Price Target
Short Interest
Healthy
23.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.37mentions of Adicet Bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$261,135 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.78) to ($2.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

470th out of 1,098 stocks

Pharmaceutical Preparations Industry

217th out of 536 stocks

ACET stock logo

About Adicet Bio (NASDAQ:ACET) Stock

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ACET shares. StockNews.com cut Adicet Bio from a "hold" rating to a "sell" rating in a research note on Thursday, July 28th. TheStreet cut Adicet Bio from a "c-" rating to a "d+" rating in a research note on Wednesday, June 1st. Finally, JMP Securities reaffirmed a "buy" rating and set a $21.00 price objective on shares of Adicet Bio in a research note on Tuesday, June 7th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, Adicet Bio has an average rating of "Moderate Buy" and an average price target of $29.29.

Adicet Bio Stock Performance

Adicet Bio stock opened at $18.15 on Tuesday. The stock's 50 day simple moving average is $14.91 and its two-hundred day simple moving average is $14.54. The stock has a market cap of $726.07 million, a price-to-earnings ratio of -15.78 and a beta of 2.27. Adicet Bio has a fifty-two week low of $6.25 and a fifty-two week high of $21.17.

Adicet Bio (NASDAQ:ACET - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.17. The business had revenue of $24.99 million for the quarter, compared to analysts' expectations of $13.74 million. Adicet Bio had a negative return on equity of 13.61% and a negative net margin of 93.18%. On average, analysts predict that Adicet Bio will post -0.78 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Blake Aftab sold 6,968 shares of the business's stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $16.64, for a total transaction of $115,947.52. Following the sale, the insider now owns 45,935 shares of the company's stock, valued at $764,358.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 15,299 shares of company stock worth $261,135 in the last three months. 29.20% of the stock is owned by corporate insiders.

Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

ACET Stock News Headlines

Adicet Bio (NASDAQ:ACET) Upgraded at StockNews.com
Where Adicet Bio Stands With Analysts
Adicet Bio files for $500M mixed shelf offering
See More Headlines
Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

ACET Company Calendar

Last Earnings
5/12/2022
Today
8/09/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Sector
Medical
Current Symbol
NASDAQ:ACET
CUSIP
00444610
CIK
2034
Fax
N/A
Employees
86
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.29
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+71.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-62,000,000.00
Pretax Margin
-93.38%

Debt

Sales & Book Value

Annual Sales
$9.73 million
Book Value
$9.49 per share

Miscellaneous

Free Float
28,323,000
Market Cap
$681.60 million
Optionable
Optionable
Beta
2.27














ACET Stock - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACET shares.
View ACET analyst ratings
or view top-rated stocks.

What is Adicet Bio's stock price forecast for 2022?

7 analysts have issued twelve-month price targets for Adicet Bio's shares. Their ACET share price forecasts range from $21.00 to $34.00. On average, they anticipate the company's share price to reach $29.29 in the next twelve months. This suggests a possible upside of 61.4% from the stock's current price.
View analysts price targets for ACET
or view top-rated stocks among Wall Street analysts.

How has Adicet Bio's stock price performed in 2022?

Adicet Bio's stock was trading at $17.49 at the start of the year. Since then, ACET shares have increased by 3.8% and is now trading at $18.15.
View the best growth stocks for 2022 here
.

When is Adicet Bio's next earnings date?

Adicet Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our ACET earnings forecast
.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) issued its quarterly earnings results on Thursday, May, 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.17. The firm had revenue of $24.99 million for the quarter, compared to the consensus estimate of $13.74 million. Adicet Bio had a negative net margin of 93.18% and a negative trailing twelve-month return on equity of 13.61%.

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include Marin Software (MRIN), FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

What is Adicet Bio's stock symbol?

Adicet Bio trades on the NASDAQ under the ticker symbol "ACET."

Who are Adicet Bio's major shareholders?

Adicet Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Cowen AND Company LLC (6.11%), Candriam S.C.A. (3.21%), Assenagon Asset Management S.A. (2.19%), Jackson Creek Investment Advisors LLC (0.14%), Russell Investments Group Ltd. (0.13%) and Victory Capital Management Inc. (0.06%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Chen Schor, Francesco Galimi and Jay P Elliott.
View institutional ownership trends
.

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adicet Bio's stock price today?

One share of ACET stock can currently be purchased for approximately $18.15.

How much money does Adicet Bio make?

Adicet Bio (NASDAQ:ACET) has a market capitalization of $726.07 million and generates $9.73 million in revenue each year. The company earns $-62,000,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How many employees does Adicet Bio have?

Adicet Bio employs 86 workers across the globe.

How can I contact Adicet Bio?

Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The official website for the company is www.aceto.com. The company can be reached via phone at (857) 315-5528 or via email at jburfening@lhai.com.

This page (NASDAQ:ACET) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.